Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02957968
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:29:07.220992+00:00
Published At
2023-11-09T00:00:00+00:00
Record Updated At
2026-04-21
Results Posted At
2023-11-09
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Breast Adenocarcinoma", "Estrogen Receptor- Negative Breast Cancer", "Estrogen Receptor-positive Breast Cancer", "HER2/Neu Negative", "Invasive Breast Carcinoma", "Progesterone Receptor Negative", "Progesterone Receptor Positive Tumor", "Stage II Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Triple-negative Breast Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-21"
protocolSection.identificationModule.nctId
"NCT02957968"
protocolSection.identificationModule.officialTitle
"T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2023-11-09"

Study condition terms

  • Breast Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Estrogen Receptor- Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Estrogen Receptor-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • HER2/Neu Negative (protocolSection.conditionsModule.conditions)
  • Invasive Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Progesterone Receptor Negative (protocolSection.conditionsModule.conditions)
  • Progesterone Receptor Positive Tumor (protocolSection.conditionsModule.conditions)
  • Stage II Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIA Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIB Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Breast Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Breast Cancer (protocolSection.conditionsModule.conditions)
  • Triple-negative Breast Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.